Emyria (ASX:EMD)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Emyria.
RELATED STOCKHEAD STORIES
Health Check: Fisher & Paykel Healthcare defies the hospital cost crunch with record revenue
The Ethical Investor: Family offices, led by Aussie moguls, drive sustainability investments
Psilocybin can tackle brain injuries and binge eating, and these ASX companies are in the game
Health Check: Good golly Miss Molly! Emyria says Ecstasy works for PTSD, months after treatment
Could Trump’s second act boost these ASX psychedelic stocks?
Biocurious: From drug prices to efficiency drives, ASX biotechs await the ‘Trumpcare’ health fallout
Health Check: Actinogen powers ahead with key Alzheimer’s disease trial
Health Check: Could the White House be about to welcome LSD and magic mushrooms into the Oval Office?
Alive and Kicking: Lumos Diagnostics attracts ‘Twiggy’ Forrest as cornerstone holder in $10m raise
ASX Health Stocks: Imugene reveals promise in lymphoma trial, stock soars 27pc
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
Market Highlights: ECB cuts rates, blow to psychedelics, and 5 ASX small caps to watch today
Rise and Shine: Everything you need to know before the ASX opens
